MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the year ending 2025-12-31, AURX had $265,232 increase in cash & cash equivalents over the period. -$1,139,727 in free cash flow.

Cash Flow Overview

Change in Cash
$265,232
Free Cash flow
-$1,139,727
Unit: Dollar
Positive Cash Flow Breakdown
    • Deferred revenue
    • Net proceeds from issuance of co...
    • Net proceeds from note payable i...
    • Others
Negative Cash Flow Breakdown
    • Accounts receivable, net
    • Purchases of property and equipm...
    • Inventory, net
    • Operating lease liabilities

Cash Flow
2025-12-31
Net loss
-2,512,216
Depreciation expense
85,463
Stock-based compensation
85,986
Provision for credit losses
91,401
Provision for inventory obsolescence
19,371
Vendor expense settled in shares of common stock
51,000
Gain on settlement of accounts payable
0
Amortization of operating lease right of use assets
71,476
Accounts receivable, net
404,863
Inventory, net
82,690
Prepaid expenses and other current assets
-103,676
Accounts payable
216,893
Accrued expenses
201,392
Deferred revenue
1,275,000
Operating lease liabilities
-66,860
Net cash used in operating activities
-864,971
Purchases of property and equipment
274,756
Net cash used in investing activities
-274,756
Net proceeds from issuance of common stock
791,418
Net proceeds from option exercises
113,541
Net proceeds from note payable issuance related party-Nonrelated Party
300,000
Net proceeds from note payable issuance related party-Related Party
200,000
Net proceeds from warrant exercise
0
Net cash provided by financing activities
1,404,959
Net decrease in cash
265,232
Cash, beginning of period
283,714
Cash, end of period
548,946
Unit: Dollar.

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Net proceeds fromissuance of common stock$791,418 Net proceeds fromnote payable...$300,000 Net proceeds fromnote payable...$200,000 Net proceeds fromoption exercises$113,541 Net cash provided byfinancing activities$1,404,959 Net decrease in cash$265,232 Canceled cashflow$1,139,727 Deferred revenue$1,275,000 Accounts payable$216,893 Accrued expenses$201,392 Prepaid expenses andother current assets-$103,676 Provision for creditlosses$91,401 Stock-based compensation$85,986 Depreciation expense$85,463 Amortization of operatinglease right of use...$71,476 Vendor expense settledin shares of common...$51,000 Provision for inventoryobsolescence$19,371 Net cash used inoperating activities-$864,971 Net cash used ininvesting activities-$274,756 Canceled cashflow$2,201,658 Net loss-$2,512,216 Purchases of property andequipment$274,756 Accounts receivable, net$404,863 Inventory, net$82,690 Operating leaseliabilities-$66,860

Nuo Therapeutics, Inc. (AURX)

Nuo Therapeutics, Inc. (AURX)